Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib plus capecitabine in advanced solid tumors and HER2-negative metastatic breast cancer
2009-011878-15Phase 2Completed
- Sponsor
- Wyeth
- Start
- Jul 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bosutinib and capecitabine in breast cancer, pancreatic cancer (PC), colorectal cancer (CRC) and 3 more, sponsored by Wyeth. Primary endpoints: Overall response rate, Safety and tolerability and 1 more. Started Jul 2009; status: completed.
02
Drugs
bosutinibcapecitabine
03
Conditions
breast cancerpancreatic cancer (PC)colorectal cancer (CRC)cholangiocarcinoma (CCA)glioblastoma (GBM)
Beyond the preview
Go deeper on 2009-011878-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011878-15.